Skip to content
Screener

Jazz Pharmaceuticals JAZZ Q1 2026 Annual earnings

Reported May 5, 2026 · After market close

Revenue$1.1BBeat by $90.2M
EPS$6.34Beat by $1.67
Revenue estimate$978.7M
EPS estimate$4.67

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$1.2B
EPS estimate$6.47

Financials

Q1 2026

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$11.64B+54.4%
Enterprise value$16.37B+47.7%
P/S2.6×+0.8×

Profitability

See full
FCF margin28.6%-8.6pp

Returns & leverage

See full
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Segments

By product

See full
Xywav$408.2M+18.4%
Epidiolex/Epidyolex$249.8M+14.7%
Rylaze/Enrylaze$103.7M+10.1%
Zepzelca$101.0M+60.3%
Defitelio/defibrotide$47.4M+16.5%

By geography

See full
Europe$92.4M+10.5%
All other$16.7M+2.5%

FAQ

When did Jazz Pharmaceuticals report Q1 2026 earnings?
Jazz Pharmaceuticals (JAZZ) reported Q1 2026 earnings on May 5, 2026 after market close.
What were Jazz Pharmaceuticals's Q1 2026 revenue and EPS?
Jazz Pharmaceuticals reported revenue of $1.1B and eps of $6.34 for Q1 2026.
Did Jazz Pharmaceuticals beat estimates in Q1 2026?
Revenue beat the consensus estimate of $978.7M by $90.2M. EPS beat the consensus estimate of $4.67 by $1.67.
How did Jazz Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 19.1% from $897.8M a year earlier and eps grew 277.4% from $1.68.
Where can I find Jazz Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001232524-26-000024) and the 10-K/A periodic report (0001628280-26-027205) directly on SEC EDGAR. The filing index links above go to sec.gov.